The 14 most recent market catalysts affecting $NUVB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 85
Nuvation Bio shares are trading higher after the company announced the FDA approval of its sNDA for IBTROZI with updated duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer.
This FDA approval is a major positive catalyst for Nuvation Bio, as it expands the market for IBTROZI and validates its efficacy, especially with the updated duration of response d…
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio's stock surged over 6% after the FDA approved a supplemental New Drug Application for its oncology drug IBTROZI (taletrectinib), four months ahead of schedule. This ap…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 65
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC
Nuvation Bio released new subgroup analyses from its pivotal TRUST-I and TRUST-II studies for IBTROZI, a drug targeting ROS1-positive non-small cell lung cancer. The key finding is…
Sep 4, 2026
Corporate Catalyst
Neutral
Impact 55
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
This filing reports Jim Cramer's stock opinions from his 'Mad Money Lightning Round.' Cramer labeled Nuvation Bio (NUVB) as a 'pure spec,' which could lead to negative short-term s…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 55
Cantor Fitzgerald Initiates Coverage On Nuvation Bio with Overweight Rating
Cantor Fitzgerald analyst Li Watsek has initiated coverage on Nuvation Bio (NUVB) with an 'Overweight' rating. This event is significant because new analyst coverage, especially wi…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
Nuvation Bio Says FDA Grants Fast Track Designation For Safusidenib, Investigational, Oral, Brain-Penetrant Selective Inhibitor Of Mutant IDH1
Nuvation Bio received Fast Track Designation from the FDA for safusidenib, its drug targeting IDH1-mutant glioma. This is a significant positive development as Fast Track status ca…
Aug 18, 2026
Corporate Catalyst
Neutral
Impact 65
JP Morgan Initiates Coverage On Nuvation Bio with Overweight Rating, Announces Price Target of $13
JP Morgan analyst Priyanka Grover initiated coverage on Nuvation Bio (NUVB) with an 'Overweight' rating and set a price target of $13. This event is significant for Nuvation Bio as…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Nuvation Bio, Raises Price Target to $20
RBC Capital analyst Leonid Timashev has maintained an 'Outperform' rating on Nuvation Bio (NUVB) and raised the price target from $19 to $20. This action signals continued analyst …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Nuvation Bio Q2 EPS $(0.18) Beats $(0.19) Estimate, Sales $31.687M Beat $27.505M Estimate
Nuvation Bio's Q2 earnings report shows a beat on both EPS and sales estimates. While the company still reported a loss, the loss was smaller than anticipated, and more importantly…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 55
Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMO
Nuvation Bio is announcing upcoming presentations at the World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) in September and October 2026, …
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21
HC Wainwright & Co. analyst Robert Burns has maintained a 'Buy' rating on Nuvation Bio (NUVB) and increased the price target from $17 to $21. This analyst action signals continued …
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is Nuvation Bio Stock Gaining Monday?
Nuvation Bio released updated long-term Phase 2 data for safusidenib, demonstrating strong efficacy and durability in treating IDH1-mutant glioma, a type of brain tumor. The median…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 92
Nuvation Bio shares are trading higher after the company announced updated long-term follow-up data from the Phase 2 study of safusidenib in patients with chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma.
The announcement of updated long-term follow-up data from a Phase 2 study, especially for a chemotherapy- and radiotherapy-naïve patient population, is a significant positive for N…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 75
Nuvation Bio Announces Positive Updated Phase 2 Data And Expansion From Safusidenib Clinical Trial In Newly-Diagnosed Grade 2 Glioma Patients Outside The U.S.
Nuvation Bio's announcement of updated positive Phase 2 data for safusidenib is a significant corporate catalyst. The strong efficacy results (52% ORR, 79% 36-month PFS) and the ab…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.